| Cash Flow | 2026-03-27 |
|---|---|
| Net (loss) income | -14,653 |
| Depreciation and amortization | 67,593 |
| Amortization of deferred financing costs | 2,245 |
| Deferred income taxes | -11,994 |
| Stock-based compensation | 47,910 |
| Loss on change in fair value of forward repurchase contract | 0 |
| Impairment of assets held for sale | 6,590 |
| Impairment of long-lived assets | 0 |
| Provisions for inventory and expected credit losses | 10,011 |
| Change in fair value of marketable securities | 0 |
| Other non-cash reconciling items | 653 |
| Trade accounts receivable | 9,201 |
| Accounts receivable - other | 9,805 |
| Inventories | 6,267 |
| Payment to related party | -15,000 |
| Prepaid expenses and other assets | -49,417 |
| Trade accounts payable | 5,996 |
| Due to and from related party | -1,740 |
| Other changes in operating assets and liabilities, net | -41,314 |
| Net cash provided by operating activities | 163,069 |
| Purchases of property, plant and equipment | 38,176 |
| Purchases of intangible assets | 0 |
| Acquisition of business, net of cash acquired and working capital adjustment | 0 |
| Investment in debt security | 3,541 |
| Sales in marketable securities | 0 |
| Net cash used in investing activities | -41,717 |
| Borrowings of 2023 term loan facility, net of deferred financing costs | 0 |
| Repayment of 2020 term loan facility | 0 |
| Net proceeds from 2026 refinanced term loan facility | 285,000 |
| Repayment of term loan | 345,000 |
| Repayments of other debt | 0 |
| Finance lease payments | 1,368 |
| Receipts on related party notes receivable | 0 |
| Payments for intangible assets | 5,000 |
| Payments for taxes related to net share settlement of equity awards | 12,612 |
| Proceeds from issuance of common stock under employee purchase plan | 3,337 |
| Repurchases of common stock | 0 |
| Net proceeds from issuance of common stock | 0 |
| Payments for taxes related to repurchase of common stock | 1,713 |
| Dividends paid to non-controlling interest | 23 |
| Payments of debt issuance costs | 0 |
| Net cash (used in) provided by financing activities | -77,379 |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | 277 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | 44,250 |
| Cash and cash equivalents and restricted cash at beginning of period | 131,107 |
| Cash and cash equivalents and restricted cash at end of period | 175,357 |
ALLEGRO MICROSYSTEMS, INC. (ALGM)
ALLEGRO MICROSYSTEMS, INC. (ALGM)